Fetal Tissue Research

The central issue of the Bush administration's moratorium on fetal tissue research (Marcia Clemmitt, The Scientist, July 20, 1992, page 1) is whether the use of fetal tissue from elective abortions will encourage women to have an abortion they might not otherwise undergo. Explaining his recent veto of a bill permitting the use of fetal tissue, Bush said the bill "is inconsistent with our nation's deeply held beliefs." In 1987, the National Institutes of Health spent more than $11 million on f

Written byChristopher Scott
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

The central issue of the Bush administration's moratorium on fetal tissue research (Marcia Clemmitt, The Scientist, July 20, 1992, page 1) is whether the use of fetal tissue from elective abortions will encourage women to have an abortion they might not otherwise undergo. Explaining his recent veto of a bill permitting the use of fetal tissue, Bush said the bill "is inconsistent with our nation's deeply held beliefs."

In 1987, the National Institutes of Health spent more than $11 million on fetal tissue research and continues to spend millions on nontherapeutic research using tissue obtained legally from either spontaneous or elective abortions, according to the "Report of the NIH Ad Hoc Panel on Human Fetal Tissue Research," submitted Dec. 14, 1988, to the NIH director's advisory committee. If, as Bush claims, the issue is an ethical and philosophical one, why does his administration permit, even encourage, research using tissue from ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies